Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nitazoxanide for Cryptosporidium Parvum in HIV Infected Children
NCT00055107Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of nitazoxanide in cryptosporidiosis (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Safety as evaluated by Grade 4 or new Grade 3 adverse reactions at Day 56 and Area Under the Curve. Status: completed.
02
Drugs
nitazoxanide
03
Conditions
cryptosporidiosis
Beyond the preview
Go deeper on NCT00055107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00055107.